Ogilvie syndrome medical therapy

Jump to navigation Jump to search
Ogilvie syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Ogilvie syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ogilvie syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ogilvie syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ogilvie syndrome medical therapy

CDC on Ogilvie syndrome medical therapy

Ogilvie syndrome medical therapy in the news

Blogs on Ogilvie syndrome medical therapy

Directions to Hospitals Treating Ogilvie syndrome

Risk calculators and risk factors for Ogilvie syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]

Overview

Medical Therapy

Supportive care

  • Supportive care is recommended in patients with colonic pseduo-obstruction in order to prevent the development of serious complications like intestinal perforation. It can be performed in the first few days after diagnosing the colonic pseudo-obstruction as long as there is no severe pain or extreme abdominal distension.[1]
  • The supportive measures include the following:[2]
    • Following up and management any underlying cause like heart failure or infection
    • Terminating any concurrent medication that may cause intestinal dysmotility like opoids and calcium channel blockers
    • Administration of intravenous saline and fluids in order to preserve the normal body homeostasis
    • Placement of the patients in a prone position with elevation of the hips

Medical therapy

Neostigmine

  • The first management approach of Ogilvie's syndrome is the supportive care. If the pseudo-obstruction remains refractory, neostigmine is recommended.
  • Neostigmine is an antidote, cholinergic cholinesterase inhibitor and autonomic central nervous system agent that is FDA approved for the treatment of the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery.[3]
  • Common adverse reactions include hypotension, nausea, bradycardia, and vomiting. Hereby, atropine should be administrated when need for adverse effects reversal.[4]
  • Preferred regimen: 2mg slow IV infusion for interval of 3 to 5 minutes.

Decompression techniques

  • A last management approach (before the surgical option) for the colonic pseudo-obstruction is the non surgical decompression of the obstruction.
  • Non surgical decompression can be performed through the following:
    • Colonoscopic decompression:[5]
      • Although decompression of the obstruction using the colonoscopy is difficult, it has shown high success rates in some studies.
      • Colonoscopic decompression must be performed carefully due to risk of perforation. Moreover, no administration of oral substances or enemas before the colonoscopy procedure to prevent the risk of aspiration.
    • Percutaneous decompression :

References

  1. Eisen GM, Baron TH, Dominitz JA, Faigel DO, Goldstein JL, Johanson JF; et al. (2002). "Acute colonic pseudo-obstruction". Gastrointest Endosc. 56 (6): 789–92. PMID 12447286.
  2. Sloyer AF, Panella VS, Demas BE, Shike M, Lightdale CJ, Winawer SJ; et al. (1988). "Ogilvie's syndrome. Successful management without colonoscopy". Dig Dis Sci. 33 (11): 1391–6. PMID 3180976.
  3. Rausch ME, Troiano NH, Rosen T (2007). "Use of neostigmine to relieve a suspected colonic pseudoobstruction in pregnancy". J Perinatol. 27 (4): 244–6. doi:10.1038/sj.jp.7211669. PMID 17377607.
  4. Saunders MD, Kimmey MB (2005). "Systematic review: acute colonic pseudo-obstruction". Aliment Pharmacol Ther. 22 (10): 917–25. doi:10.1111/j.1365-2036.2005.02668.x. PMID 16268965.
  5. Jetmore AB, Timmcke AE, Gathright JB, Hicks TC, Ray JE, Baker JW (1992). "Ogilvie's syndrome: colonoscopic decompression and analysis of predisposing factors". Dis Colon Rectum. 35 (12): 1135–42. PMID 1473414.